Sionna Therapeutics stock plunged 92% after its cystic fibrosis drug flopped in a mid-stage trial
The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study
We haven't written up this one. Quartz has the full story — the link below goes straight to it.